GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » Cash Flow from Investing

Jafron Biomedical Co (SZSE:300529) Cash Flow from Investing : ¥-1,062 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Jafron Biomedical Co spent ¥96 Mil on purchasing property, plant, equipment. It gained ¥0 Mil from selling property, plant, and equipment. It spent ¥0 Mil on purchasing business. It gained ¥0 Mil from selling business. It spent ¥1,168 Mil on purchasing investments. It gained ¥425 Mil from selling investments. It paid ¥0Mil for net Intangibles purchase and sale. And it paid ¥0 Mil for other investing activities. In all, Jafron Biomedical Co spent ¥839 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Jafron Biomedical Co Cash Flow from Investing Historical Data

The historical data trend for Jafron Biomedical Co's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co Cash Flow from Investing Chart

Jafron Biomedical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -197.13 -341.11 -670.22 -305.90 -249.65

Jafron Biomedical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.40 -35.87 -25.68 -160.71 -839.27

Jafron Biomedical Co Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Jafron Biomedical Co's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Jafron Biomedical Co's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-1,062 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jafron Biomedical Co  (SZSE:300529) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Jafron Biomedical Co's purchase of property, plant, equipment for the three months ended in Mar. 2024 was ¥-96 Mil. It means Jafron Biomedical Co spent ¥96 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Jafron Biomedical Co's sale of property, plant, equipment for the three months ended in Mar. 2024 was ¥0 Mil. It means Jafron Biomedical Co gained ¥0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Jafron Biomedical Co's purchase of business for the three months ended in Mar. 2024 was ¥0 Mil. It means Jafron Biomedical Co spent ¥0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Jafron Biomedical Co's sale of business for the three months ended in Mar. 2024 was ¥0 Mil. It means Jafron Biomedical Co gained ¥0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Jafron Biomedical Co's purchase of investment for the three months ended in Mar. 2024 was ¥-1,168 Mil. It means Jafron Biomedical Co spent {stock_data.stock.currency_symbol}}1,168 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Jafron Biomedical Co's sale of investment for the three months ended in Mar. 2024 was ¥425 Mil. It means Jafron Biomedical Co gained ¥425 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Jafron Biomedical Co's net Intangibles purchase and sale for the three months ended in Mar. 2024 was ¥0 Mil. It means Jafron Biomedical Co paid ¥0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Jafron Biomedical Co's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0 Mil. It means Jafron Biomedical Co paid ¥0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Jafron Biomedical Co's cash from other investing activities for the three months ended in Mar. 2024 was ¥0 Mil. It means Jafron Biomedical Co paid ¥0 Mil for other investing activities.


Jafron Biomedical Co Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Jafron Biomedical Co's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Jafron Biomedical Co (SZSE:300529) Business Description

Traded in Other Exchanges
N/A
Address
No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085
Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.
Executives
Li Feng Director
He Xiao Lian Executives
Dong Fan Directors, Directors, and Executives
Ceng Kai Directors, executives
Tang Xian Min Directors, executives
Zhang Ming Yuan Secretary Dong
Fang Li Hua Supervisors
Zhang Guang Hai Directors, executives
Li De Zhi Executives
Lu Shao Zhang Executives

Jafron Biomedical Co (SZSE:300529) Headlines

No Headlines